Topic Hub
4 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 4 of 4 clinical reviews.
A critical analysis of the MAESTRO-NASH trial's enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest considerations for resmetirom in MASH.
Read clinical reviewA detailed breakdown of the MAESTRO-NASH trial results for resmetirom in MASH, covering primary and secondary endpoints, effect sizes, confidence intervals, subgroup analyses, and response distribution.
Read clinical reviewA deep-dive into the MAESTRO-NASH phase 3 trial of resmetirom (Rezdiffra) for MASH with liver fibrosis, covering methodology, histological endpoints, safety data, and clinical implications.
Read clinical reviewDeep-dive into the MAESTRO-NASH trial of resmetirom for MASH: how FDA approval reshapes prescribing, which guidelines updated, and what clinicians should know beyond the abstract.
Read clinical review